Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer
July 15th 2022
Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.